Answers are grounded in this paper and cite their sources.
Adverse drug reactions (ADRs) are a significant public health issue, contributing substantially to patient morbidity and mortality. The growing accessibility of genomic technologies has greatly advanced our understanding of the genetics underlying ADRs. Pharmacogenomics, which investigates how genetic polymorphisms influence individual responses to drug therapy on a genome-wide scale, plays a pivotal role in this field. The article summarizes the relationship between ADRs and genes, outlines the current applications and advancements of pharmacogenomics in the prediction, diagnosis, prevention, regulation, and personalized treatment of ADRs, and reviews cutting-edge research methods and large-scale international studies. These insights aim to provide a reference for the future development of pharmacogenomics in ADR research. • Genetic polymorphisms can affect individual's response to drug therapy at the genome-wide level. • Pharmacogenomics plays an important role in explaining, predicting and reducing ADRs. • The combination of pharmacogenomics and pharmacovigilance has been widely used around the world. • More cutting-edge research and large-scale international collaboration can promote accurate and rational medication use
No takes yet. Share an insight, caveat, or question.
Bi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: